Aktie A180400 DX & VX CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Dx & Vx Co., Ltd.

Aktien

A180400

KR7180400004

A180400

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 03.05.2024 		% 5 Tage % 1. Jan.
4’665 KRW +0.65% Intraday Chart für Dx & Vx Co., Ltd. +7.36% -21.07%
2023 Dx&Vx entwickelt gemeinsam mit LG CNS eine Big-Data-Plattform für den Bereich Bio-Gesundheit CI
2023 Dx & Vx Co., Ltd. (KOSDAQ:A180400) hat die Übernahme von 39,12% der Anteile an Avixgen, Inc. von einer Gruppe von Verkäufern abgeschlossen CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.
DxVx Appoints Kevin Kwon as New President
DxVx Appoints Yong Gu Lee as CEO
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A180400 Aktie
  4. Nachrichten Dx & Vx Co., Ltd.
  5. Andere Sprachen